Novavax COVID-19 vaccine, adjuvanted – New emergency use authorization
July 13, 2022 - The FDA announced the emergency use authorization (EUA) of Novavax’s COVID-19 vaccine, adjuvanted, for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.
Top